優雅道

MENU Company Company Back Company Message from Top Management Our Founding Spirit Brand Statement Our Story Our History of Value Creation Vision and Strategy Framework Group Vision Long-Term Management Strategy Management Policy Medium-Term Management Plan Corporate Information and Business Sites Business Overview Introduction of Executives Corporate Governance Group Companies Procurement Policy Corporate Policy over Internal Control Integrated Report Products and Technology Products Back Products Search by Application Mobility Architectural Materials Infrastructure / General Industry Electronics Semiconductors Energy Daily commodities, Food industry Life Science Search by Business Category Architectural Glass Automotive Display Electronic Materials Essential Chemicals Performance Chemicals Life Science Ceramics New Business Search by Name Search by Keyword Technology and Innovation back Technology and Innovation A Message from the Chief Technology Officer Technology Development Strategy Intellectual Property Strategy R&D Structure Core Technologies Technology Highlights Mobility Electronics Life Science AGC Yokohama Technical Center AGC OPEN SQUARE “AO” Overview Facility Guide Access Collaboration Research Collaboration System R&D Library Measures to Prevent Misconduct in Research and Properly Manage Public Research Funds Sustainability Sustainability Back Sustainability Protecting the Global Environment and Utilizing Resources Supporting the Evolution of Cities and Mobility Realizing Longevity Society Where People Can Live in Good Health Creating a Healthy and Secure Society through Connections Generating New Value from Fair and Safe Workplaces Message from the President and CEO The AGC Group’s Sustainability Management Sustainability Promotion System Download Report Site Reports External Evaluations GRI Standards Index Sustainability-related policies, criteria, and guidelines AGC Group Code of Conduct/Compliance Help Lines Investors Investors Back Investors Management Information To Our Shareholders Vision and Strategy Framework Business Risks Disclosure Policy Financial Highlights IR News IR Library Company Overview Presentations of Financial Results Presentations of Business Briefings Financial Results Financial Review AGC Review (Newsletter for Shareholders) ESG Information Sustainability Corporate Governance Integrated Report Stock and Bond Information Stock Information Corporate Bond and Rating Information Dividend Information Analyst Coverage General Meeting of Shareholders Methods for Various Stock Procedures Electronic Public Notice Articles of Incorporation Stock Price Contact Us FAQ IR Email News Support Information IR Calendar Cautionary Statement IR Site Map Careers News Contact EN JP CN Search September 25, 2017Management Download PDF Print AGC to Expand Production Capacity at Its Subsidiary CMC Biologics Copenhagen, Denmark Facility The strategic expansion aims to meet the increasing demand for antibody drug development and production AGC Asahi Glass (AGC), a world-leading manufacturer of glass, chemicals and high-tech materials, announces today that it has decided to increase its capacity at CMC Biologics, a 100% subsidiary of AGC. Specifically, five single use bioreactors with 2,000L volume will be built at the production site in Denmark, allowing for flexible production with scales from 2000L to 12000L in a single production suite. The Bioreactor 6Pack can be run in single unit operations or in groups, simultaneously, sequentially or in staggered fashion to achieve desired production needs. Production is expected to be online in the third quarter of 2018.CMC Biologics, a leading CDMO, which was acquired by AGC in February, has development and manufacturing capabilities for both, mammalian and microbial. They offer value-added services from process development, small scale-up to commercial-scale production. CMC is the pioneer of the single-use bioreactor technology, which allows for contamination-free cleaning and sterilization. Currently, at its manufacturing site in Seattle, Washington, CMC Biologics has a production line that offers up to 12,000L culture scale. With this additional capacity in Copenhagen, Denmark, CMC will be able to provide large- scale commercial production by single-use bioreactors in Europe as well. “The Biopharmaceutical market is growing at above 8 % per year, with a strong demand for antibody drugs. Along with CMC Biologics, the AGC Group will expand business globally together with AGC in Japan (Chiba and Yokohama) and BIOMEVA, a CDMO with microbial capabilities in Germany, which AGC acquired in August 2017. The integration activities after the acquisitions are progressing successfully” stated Hideyuki Kurata, General Manager of Life Science General Division, Chemicals Company, AGC. Under the management policy AGC plus, the AGC Group is promoting the measures proactively, by positioning Life Science business as one of the strategic business field. In bioscience business, AGC continues to execute necessary investment in a timely manner responding to demand increase for the period ahead. Outline of CMC Biologics Company name CMC Biologics CEO Gustavo Mahler HQ location Seattle in the United States Production sites Copenhagen in Denmark, Seattle and Berkeley in the United States Controlling share AGC 100% Founded in 2001 Description of business Biopharmaceutical CDMO, Production of antibody, blood factor, recombinant vaccine, enzyme, antigen, hormone Employees Around 600 people Media inquiries Kazumi Tamaki, General Manager, Corporate Communications & Investor Relations OfficeAGC Asahi Glass Contact: Tomoko Komazaki TEL: +81-3-3218-5603 E-mail: [email protected] Share News Index HomeNewsAGC to Expand Production Capacity at Its Subsidiary CMC Biologics Copenhagen, Denmark Facility Check in AGC Site Map About Social Media Contact About This Site Privacy Policy ©AGC Inc.